OPTIMISING INDIVIDUAL DOSES OF 5-FLUORURACIL IN FOLFIRI REGIMEN Russian patent published in 2013 - IPC A61K31/505 A61P35/00 

FIELD: medicine.

SUBSTANCE: present invention refers to medicine, namely to oncology and may be used to determine a dose D (n +1) of 5-fluorouracil (5-FU) for the next therapeutic cycle (n +1) in a blood sample of the patient suffering cancer. For this purpose, each therapeutic cycle i includes: max. 500 mg/m² of bolus-dosed 5-fluorouracil (5-FU), max. 600 mg/m² of folinic acid or a salt thereof, a dose D(i) (mg/m²) of 5-FU continuously infused for 43 to 49 hours, and max. 500 mg/m² of irinotecan. The plasma 5-FU ([5-FU]) concentration is determined in vitro in a patient's blood sample in the previous therapeutic cycle n at least 1 hour after the beginning of 5-FU perfusion and to the completion thereof. D(n+1) is calculated depending on D(n) with using the below solution procedure: if [5-FU]<100 mcg/l, then D(n-H)=D(n)×1.40, if 100≤[5-FU]<200 mcg/l, then D(n+1)=D(n)×1.30, if 200≤[5-FU]<300 mcg/l, then D(n+1)=D(n)×1.20, if 300≤[5-FU]<400 mcg/l, then D(n+1)=D(n)×1.10, if 400≤[5-FU]<500 mcg/l, then D(n+1)=D(n)×1.05, if 500≤[5-FU]<600 mcg/l, then D(n+1)=D(n)×1.025, if 600≤[5-FU]<650 mcg/l, then D(n+1)=D(n), if 650≤[5-FU]<700 mcg/l, then D(n+1)=D(n)×0.975, if 700≤[5-FU]<800 mcg/l, then D(n+1)=D(n)×0.95, if 800≤[5-FU]<900 mcg/l, then D(n+1)=D(n)×0.90, if [5-FU]≥900, then D(n+1)=D(n)×0.80.

EFFECT: using the given method enables optimising the dose of 5-FU continuously infused in each FOLFIRI cycle or similar therapeutic cycle for the purpose of reducing toxicity and improving the clinical effectiveness.

1 cl, 2 ex, 2 dwg